Combinations of KRAS G12D inhibitors with irinotecan and related therapeutic methods

The present invention relates to a combination therapy for the treatment of KRas G12D cancer. Specifically, the present invention relates to a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of irinotecan (or an analog thereof) in combination with a KRas G12D inhibitor, pharmaceutical compositions comprising such compositions, kits comprising such compositions, and methods of use thereof. 本发明涉及用于治疗KRas G12D癌症的组合疗法。具体地，本发明涉及治疗有需要的受试者中的癌症的方法，所述方法包括向所述受试者施用治疗有效量的伊立替康(或其类似物)与KRas G12D抑制剂的组合，包含此类组合物的药物组合物、包括此类组合物的药盒及其使用方法。